Navigation Links
Rutgers, UMDNJ receive $23 million to develop antidotes for chemical weapons attacks

The National Institutes of Health (NIH) has awarded a five-year $23.2 million grant to a group of investigators at Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School to continue their research aimed at developing drug products that could be used against chemical warfare agents from a terrorist attack.

Members of the Environmental and Occupational Health Sciences Institute (EOHSI), Rutgers and UMDNJ-Robert Wood Johnson Medical School have been collaborating with scientists from the School of Public Health at New York Medical College and the Chemistry Department at Lehigh University for the past five years to devise therapies that could be used if deadly chemical poisons were released into the general population.

The focus of the research is the development of drugs to treat individuals exposed to mustard gas. The newly awarded funding allows these investigators who are part of the UMDNJ/Rutgers CounterACT Research Center of Excellence the opportunity to continue work begun in 2006 after the NIH granted Rutgers and UMDNJ-Robert Wood Johnson Medical School $19.2 million to establish the center and begin its research.

"This funding allows our us to continue our considerable efforts with different research groups to develop drug products that can be used successfully against a chemical terrorist attack," said Jeffrey Laskin, Professor of Environmental and Occupational Medicine at Robert Wood Johnson Medical School, and director of the center. "This is critical to preventing serious injury and death from any such attack."

The focus of the center's research is the development of drug products to treat individuals exposed to mustard gas, which causes symptoms ranging from skin irritations and conjunctivitis to severe ulcerations, blistering of the skin, blindness and irreversible damage to the respiratory tract and lungs. Mustard gas was first used by the German military against Allied troops during World War I and more recently in the Iran-Iraq conflict during the 1980s. It is easy to make and transport and is still considered a high risk terrorist threat.

"We were asked if we could apply our expertise to help address this type of national security issue," said Laskin. "There has been a lot of conversation over the years about the problems that could result from a terrorist attack and everyone realized that we needed to develop a therapy to counteract this if it happens."

The principal investigators in the UMDNJ/Rutgers CounterACT Research Center of Excellence include Director Jeffrey Laskin of UMDNJ, Co-Director Donald Gerecke at Rutgers Ernest Mario School of Pharmacy, Marion Gordon, Debra Laskin and Patrick Sinko, also at Rutgers School of Pharmacy, Diane Heck at New York Medical College, and Ned Heindel at Lehigh University. They work closely with Batelle Laboratory in Ohio, where mustard gas experiments are carried out.


Contact: Robin Lally
732-932-7084 x652
Rutgers University

Related biology news :

1. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
2. LCC science projects receive $1.2 million through WaterSMART program
3. NJIT professor working with graphene, carbon nanotubes to receive honor
4. Danforth Center Collaborative Research Program receives funding to improve crop yield in Africa
5. Marine Science Institute receives $7 Million grant to study the impact of the Deepwater Horizon
6. UC Riverside plant biotechnologist receives prestigious Jefferson Science Fellowship
7. Scientists receive grant to develop new DNA sequencing method
8. Hawaii receives funding for liver cancer research
9. CWRU School of Dental Medicine receives $2.6 million in grants
10. Mount Sinai receives $3.4 million for largest study of personalized medicine in the clinical setting
11. MegaMatcher and VeriFinger SDK Fingerprint Compression Algorithms Receive WSQ Certification from FBI Biometric Center of Excellence
Post Your Comments:
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at . 2016 Year Highlights: ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic ... one eye at a time. So which eye do you rinse first if a dangerous ... have Plum Duo Eye Wash with its unique dual eye piece. , “Whether ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
Breaking Biology Technology: